Assessment of Long-Term Infliximab for Psoriasis (P05319)

Inclusion Criteria

• •Participant must have a diagnosis of plaque-type psoriasis
• •Participant's physician must have decided, with the subject's consent, to start treatment with infliximab
• •Participant must demonstrate willingness to participate in the study and agree with the procedures of the study by signing the written informed consent
• •For inclusion into the extended treatment period, participant must have completed 50 weeks of infliximab treatment in the treatment period
• •For inclusion into the extended treatment period, participant must be continuing treatment with intravenous infliximab
• •For inclusion into the extended treatment period, participant must have an improvement in their PASI score of greater than or equal to 25% at the time of entry into to the extended treatment period
• •For the Extended Treatment Period